SEARCH:   Advanced

Blood, 15 December 2008, Vol. 112, No. 13, pp. 4839-4842. Prepublished online as a Blood First Edition Paper on September 25, 2008; DOI 10.1182/blood-2008-04-149948. This Article Full Text (PDF) All Versions of this Article: blood-2008-04-149948v1 112/13/4839    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jabbour, E. Articles by Cortes, J. Search for Related Content PubMed PubMed Citation Articles by Jabbour, E. Articles by Cortes, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 4, 2008 Accepted September 3, 2008 Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Neeli Reddy, Susan O'Brien, Guillermo Garcia-Manero, Jan Burger, and Jorge Cortes* Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States * Corresponding author; email: jcortes{at}mdanderson.org. Mutations in codon 317 have been reported following treatment with imatinib and dasatinib. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20: 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (p=0.001). Median follow-up from mutation detection was 25 months. At the time of F317L, 8 patients were in chronic (CP), 6 in accelerated, and 6 in blast phase. There was no difference in characteristics between patients with or without F317L mutations, or no mutations. All patients failed dasatinib therapy and 4/6 (67%) responded to nilotinib; 2 responded to imatinib dose-escalation. Survival of patients with F317L was similar to those with other mutations (p=0.45). Patients in CP had better outcome with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKI. The prognosis is mostly dependent on the disease stage. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Jabbour, D. Jones, H. M. Kantarjian, S. O'Brien, C. Tam, C. Koller, J. A. Burger, G. Borthakur, W. G. Wierda, and J. Cortes Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Blood, September 3, 2009; 114(10): 2037 - 2043. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020